63 related articles for article (PubMed ID: 24854489)
1. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy for Tumor Control in Well-Differentiated Metastatic Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Q and A.
Del Rivero J; Kennedy EB; Perez K
JCO Oncol Pract; 2023 Nov; 19(11):955-958. PubMed ID: 37774321
[No Abstract] [Full Text] [Related]
3. Correction: Zhao et al. Hypermethylation of UCHL1 Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing Degradation of Cortactin (CTTN).
Zhao Y; Lei Y; He SW; Li YQ; Wang YQ; Hong XH; Liang YL; Li JY; Chen Y; Luo WJ; Zhang PP; Yang XJ; He QM; Ma J; Liu N; Tang LL
Cells; 2024 May; 13(10):. PubMed ID: 38786107
[TBL] [Abstract][Full Text] [Related]
4. Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors.
Lim JY; Pommier RF
Front Endocrinol (Lausanne); 2021; 12():622693. PubMed ID: 33732215
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
Tessier-Cloutier B; Cochrane DR; Karnezis AN; Colborne S; Magrill J; Talhouk A; Zhang J; Leung S; Hughes CS; Piskorz A; Cheng AS; Greening K; du Bois A; Pfisterer J; Soslow RA; Kommoss S; Brenton JD; Morin GB; Gilks CB; Huntsman DG; Kommoss F
Hum Pathol; 2020 Jul; 101():40-52. PubMed ID: 32360491
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
[TBL] [Abstract][Full Text] [Related]
7. Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors.
Buicko JL; Finnerty BM; Zhang T; Kim BJ; Fahey TJ; Nancy Du YC
Ann Pancreat Cancer; 2019 Jun; 2():. PubMed ID: 31535089
[TBL] [Abstract][Full Text] [Related]
8. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors.
Sansone A; Lauretta R; Vottari S; Chiefari A; Barnabei A; Romanelli F; Appetecchia M
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31382663
[TBL] [Abstract][Full Text] [Related]
9. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms.
Mafficini A; Scarpa A
Endocr Rev; 2019 Apr; 40(2):506-536. PubMed ID: 30657883
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective.
Finnerty BM; Gray KD; Moore MD; Zarnegar R; Fahey Iii TJ
World J Gastrointest Oncol; 2017 Sep; 9(9):341-353. PubMed ID: 28979716
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors.
Song YL; Yu R; Qiao XW; Bai CM; Lu CM; Xiao Y; Zhong DR; Chen J; Zhao YP; Zhang TP; Song TT; Gao HL; Wan YH; Shen L; Chen J; Lv B; Hao JJ; Zhang Y; Tang L; Chen YJ
Sci Rep; 2017 May; 7(1):2205. PubMed ID: 28526880
[TBL] [Abstract][Full Text] [Related]
12. An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: a case report.
Celotti A; Pulcini G; Schieppati M; Ministrini S; Berruti A; Ronconi M
World J Surg Oncol; 2015 May; 13():169. PubMed ID: 25933800
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
[TBL] [Abstract][Full Text] [Related]
14. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.
Trifa F; Karray-Chouayekh S; Jmaa ZB; Jmal E; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Med Oncol; 2013 Mar; 30(1):418. PubMed ID: 23315218
[TBL] [Abstract][Full Text] [Related]
15. Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors.
Moore MD; Finnerty B; Gray KD; Hoda R; Liu YF; Soong L; Beninato T; Rao R; Zarnegar R; Fahey TJ
Surgery; 2018 Jan; 163(1):226-231. PubMed ID: 29150024
[TBL] [Abstract][Full Text] [Related]
16. The molecular genetics of gastroenteropancreatic neuroendocrine tumors.
Zikusoka MN; Kidd M; Eick G; Latich I; Modlin IM
Cancer; 2005 Dec; 104(11):2292-309. PubMed ID: 16258976
[TBL] [Abstract][Full Text] [Related]
17. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.
Klöppel G; Rindi G; Anlauf M; Perren A; Komminoth P
Virchows Arch; 2007 Aug; 451 Suppl 1():S9-27. PubMed ID: 17684761
[TBL] [Abstract][Full Text] [Related]
18. Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.
Kleiman DA; Beninato T; Sultan S; Crowley MJ; Finnerty B; Kumar R; Panarelli NC; Liu YF; Lieberman MD; Seandel M; Evans T; Elemento O; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S672-9. PubMed ID: 24854489
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
